Background and Aims
Endoscopic therapy is emerging as an alternative to surgical therapy in patients with mucosal (T1a) esophageal adenocarcinoma (EAC) given the low likelihood of lymph node metastases. Long term outcomes of patients treated endoscopically and surgically for mucosal EAC are unknown. We compared long term outcomes of patients with mucosal EAC treated endoscopically and surgically.
Methods
Patients treated for mucosal EAC between 1998 and 2007 were included. Patients were divided into an ENDO group (treated endoscopically) and a SURG group (treated surgically). Vital status information was queried using an institutionally approved internet research and location service. Statistical analysis was performed using Kaplan Meier curves and Cox proportional hazards ratios.
Results
176 patients were included of which 132 (74 %) were in the ENDO group and 46 (26 %) were in the SURG group. Mean follow up was 64 months (SEM 4.8) in the SURG group and 43 months (SEM 2.8) in the ENDO group. Cumulative mortality in the ENDO group (17%) was comparable to the SURG group (20 %) (p=0.75). Overall survival was also comparable using the Kaplan Meier method. Treatment modality was not a significant predictor of survival on multivariable analysis. Recurrent carcinoma was detected in 12% of patients in the ENDO group, all successfully re-treated without impact on overall survival.
Conclusions
Overall survival in patients with mucosal EAC when treated endoscopically appears to be comparable to that of patients treated surgically. Recurrent carcinoma occurs in a limited proportion of patients, but can be managed endoscopically.